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Vaccination is the most cost effective control measure for Johne’s disease caused by Mycobacterium avium subspecies
paratuberculosis (MAP) but currently available whole cell killed formulations have limited efficacy and are incompatible
with the diagnosis of bovine tuberculosis by tuberculin skin test. We have evaluated the utility of a viral delivery
regimen of non-replicative human Adenovirus 5 and Modified Vaccinia virus Ankara recombinant for early entry MAP
specific antigens (HAV) to show protection against challenge in a calf model and extensively screened for differential
immunological markers associated with protection. We have shown that HAV vaccination was well tolerated, could be
detected using a differentiation of infected and vaccinated animals (DIVA) test, showed no cross-reactivity with
tuberculin and provided a degree of protection against challenge evidenced by a lack of faecal shedding in vaccinated
animals that persisted throughout the 7 month infection period. Calves given HAV vaccination had significant priming
and boosting of MAP derived antigen (PPD-J) specific CD4+, CD8+ IFN-γ producing T-cell populations and, upon
challenge, developed early specific Th17 related immune responses, enhanced IFN-γ responses and retained a high
MAP killing capacity in blood. During later phases post MAP challenge, PPD-J antigen specific IFN-γ and Th17 responses
in HAV vaccinated animals corresponded with improvements in peripheral bacteraemia. By contrast a lack of IFN-γ,
induction of FoxP3+ T cells and increased IL-1β and IL-10 secretion were indicative of progressive infection in Sham
vaccinated animals. We conclude that HAV vaccination shows excellent promise as a new tool for improving control
of MAP infection in cattle.Introduction
Mycobacterium avium subspecies paratuberculosis (MAP)
is the causative agent of Johne’s disease (JD), a chronic
granulomatous inflammation of the intestines primarily
in ruminants [1] and which has been linked to Crohn’s
disease in humans [2]. The increasing prevalence of MAP
infection in cattle, the associated economic losses and
zoonotic potential indicate the need for an effective MAP
vaccine as a sustainable and economically viable solution
for disease control [3]. Whole cell killed MAP vaccines
can improve milk productivity [4] reduce the incidence of* Correspondence: tim.bull@sgul.ac.uk
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unless otherwise stated.clinical JD [5] and faecal abundance of MAP [6], however
the proportion of animals harbouring and excreting MAP
remain similar [7]. Attempts to provide live attenuated
whole cell vaccines have mostly been ineffective [3]. Al-
though some have shown promise in goats [8], none have
been able to eliminate faecal excretion. This is an import-
ant pre-requisite, however recent modelling studies indi-
cate that to achieve effective MAP control in cattle in the
shortest time period, priority should be given to vaccines
that are able to reduce susceptibility to MAP infection [9].
In contrast, vaccines targeted at only reducing clinical
cases and decreasing but not eliminating MAP shedding
would not be economically beneficial to dairy producers
when compared with an alternative non-vaccine control,
particularly when herds were highly infected with MAP. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ive capacity as an ability of vaccination to reduce bacterial
numbers in peripheral blood, gut tissues and in faeces as
this is likely to impact significantly on disease progression
and transmission.
Importantly whole cell MAP vaccines contain generic
mycobacterial cell wall antigens cross-reactive with tuber-
culin [11] used in diagnostic testing for bovine tubercu-
losis caused by Mycobacterium bovis. In addition animals
vaccinated with whole cell MAP vaccines cannot be differ-
entiated, using current diagnostic tests, from MAP in-
fected animals and there is therefore a need for any new
MAP vaccine to have a Differentiation of Infected from
Vaccinated Animals (DIVA) test capability [12]. Eradica-
tion programs are currently impossible whilst inter-animal
spread and seeding into environmental or wildlife reser-
voirs remains high. Therefore whole cell vaccines have
limited value in cattle control programmes given their
limited efficacy and their interference with current bovine
TB diagnostics, particularly in areas with ongoing endemic
bovine tuberculosis [13].
Of increasing importance is the understanding that
MAP disease involves an insidious onset of dysregula-
tory immune mechanisms that need to be normalised or
prevented from accumulating if protection is to be
achieved. Comparisons with studies in other mycobac-
terial diseases suggest lasting effective immunity would
require combinations of humoral and mucosal immunity
along with priming and maintenance of pathogen spe-
cific Th1 responses [14]. Development of an effective
vaccine thus requires rational, focused design using
novel delivery methods able to circumvent dysregulated
antigen priming invoked during MAP persistence whilst
specifically targeting and enhancing the crucial immuno-
logical processes able to arrest pathogenesis.
The ability of viral vectored vaccines to positively ad-
dress these processes has already shown promise in other
mycobacterial diseases including cattle [15-17]. Viral de-
livery provides the advantages of high antigen delivery to
antigen presenting cells [18], increased antigen specific
CD4+ and CD8+ responses [19,20] and maintenance of
IFN-γ release driving increased macrophage activation
and killing capacity [21]. Prime-boost vaccination with
MVA-Ag85A induced altered Th1/Th17 related responses
[22] that were shown to correlate with the induction of
protective immunity [17].
We have previously demonstrated that a priming vac-
cination with non-replicative Adenovirus 5 followed by
boosting with Modified Vaccinia virus Ankara delivery
vectors expressing a fusion of critical epitopes from four
intracellular phase codon optimised MAP antigens (HAV)
was able to confer both therapeutic and prophylactic pro-
tection against MAP challenge in mice [23]. In this study
we evaluate the same prime boost strategy in cattle andinvestigate immunological responses associated with pro-
tection. We show that HAV vaccination was well toler-
ated, could be detected by DIVA testing, did not cross
react with the tuberculin test and provided a high degree
of protection against challenge evidenced by a lack of fae-
cal shedding that persisted throughout the 38-week test
period.
Materials and methods
Vaccine construction and manufacture
HAV vaccine comprised non replicative human adeno-
virus serotype 5 (Ad5) and Modified Vaccinia virus
Ankara (MVA) expressing a 838aa polypeptide fusion of
regions sourced from four non-essential, non-toxigenic,
immunogenic, early intracellularly expressed MAP pro-
teins with no significant BLASTP homologies to either
mammalian or known tuberculosis PPD proteins [11].
Vaccine design and production including extensive codon
optimisation and addition of expression enhancement fea-
tures were as described previously [23]. Vaccine doses
were derived from a single batch preparation manufac-
tured at the Viral Vector Core Facility, Jenner Institute,
Oxford, UK from seed stocks using specific pathogen free
CEF and T-Rex 293A cell lines for MVA and Ad5 respect-
ively in certified pathogen free media. Ad5 and MVA vec-
tors expressing GFP in place of the HAV polypeptide were
manufactured in parallel to a similar viral titre and used
for Sham vaccination.
Preparation of MAP challenge inoculum
A strain of MAP (R0808) isolated from a cow with JD was
inoculated into modified liquid Middlebrooks 7H9 medium
[24] and grown at 37 °C with gentle agitation to an OD600
of 1.8. The culture was extensively passed through a 20G
needle and any remaining large clumps were allowed to set-
tle for 5 min. The upper suspension was then separated
and adjusted to an OD600 of 1.0 with sterile PBS then ali-
quoted in 5 mL doses. qPCR using MAP specific primers
(see below) estimated that each dose contained 5 × 108
MAP genome equivalents of MAP organisms. Prior to dos-
ing aliquots were centrifuged at 3500 × g for 10 min and
the pellet resuspended with a syringe into 20 mL of PBS.
Vaccination, challenge and sampling regimen
Calves were selected from herds with an absence of tuber-
culin skin test reactivity over the previous 10 years, and
without bovine tuberculosis disclosed at abattoir over the
same period. These same herds were selected on the basis
that increases in skin thickness following injection of
PPD-A were minimal, below 4 mm, indirectly indicating
an absence of immune responses to MAP. Eight week old
male Holstein Friesian calves in two groups of six were
held under regulated category containment at AFBINI,
Stormont, Northern Ireland and vaccinated intradermally
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mL) at week -11 and boosted with MVA.HAV (109 pfu/
mL) at week -5 (HAV) or vaccinated with Ad5 (109 vp/mL)
and MVA (109 pfu / mL) vectors expressing GFP in the
same regime (Sham). Five weeks after boosting (week 0)
both vaccinated groups were challenged on two consecutive
days with an oral dose of 5 × 108 MAP R0808 mixed
into PBS.
Faecal and blood samples were taken immediately
prior and 1 week post- prime and boost vaccinations
and post-challenge, then monthly over the 38 week post
challenge study period. Whole bloods were processed
for IFN-γ release assays. PBMC fractions were aliquoted
and processed separately for MAP killing assays, MAP
presence using a 2 week pre-liquid culture followed by
subculture for MAP colonies on solid slopes and direct
differential lysis DNA extraction for MAP by nested
PCR, cytokine expression or presence of HAV transgene
using cDNA extractions followed by specific PCR, cyto-
kine release assays by ELISA and cell population analysis
using flow cytometry. Faecal samples were processed for
MAP presence by 2 week pre-liquid culture followed by
dividing for subculture on solid slopes and differential
lysis DNA extraction for MAP by nested PCR. Direct
DNA extraction was also performed separately on faecal
samples for HAV transgene PCR testing. Animals were
euthanized at 38 weeks post challenge and samples from
mesenteric lymph nodes, duodenum, spleen, ileum and
jejunum taken at necropsy. Tissue samples were proc-
essed for MAP load by direct differential mycobacterial
DNA extraction followed by qPCR, for cytokine expres-
sion and HAV transgene presence by PCR from cDNA
preparations and cell population analysis using flow
cytometry.
All animal husbandry and procedures were carried out
by trained and experienced animal care workers under
the direction of a senior Named Veterinary Surgeon and
in compliance with the UK Home Office Regulations in-
cluding the Animals (Scientific Procedures) Act 1986.
The study was authorized by the local Ethical Review
Committee at AFBINI, in compliance with national
guidelines and EU regulations for projects using animals
for research purposes.
Tissue preparation
All tissue samples were dissected at necropsy and, for
MAP culture and DNA isolation, were initially stored/
transported for up to two days at RT in 1 mL RPMI1640
(Sigma, Gillingham, UK) plus 10% FBS and 100 μg/mL
ampicillin. For cell isolation for flow cytometry and
RNA isolation tissues were processed immediately fol-
lowing retrieval. Fat was removed from the tissue and
mucosal tissue (if present) was scraped, washed with
PBS, diced using sterile scalpels and then weighed.Lymph nodes were gently dissociated using a scalpel and a
single cell suspension was obtained by filtration through a
70 μm cell strainer (Becton Dickinson, Oxford, UK). For
MAP culture and DNA PCR, samples were digested over-
night with slow agitation at 37 °C in 1 mL Pen/Strep free
digest buffer (0.15 mM NaCl, 0.3 mM CaCl2, 1 mg/mL
collagenase B, 1 mg/mL trypsin (Sigma)) then pelleted in
a microfuge at 16 000 × g for 5 min. For flow cytometric
analysis and host RNA extraction, ileum and ileocecal
valve tissue was digested for 80 min at 37 °C in digestion
medium (RPMI1640, 1% FBS, 25 μg/mL gentamicin,
100 U/mL Pen/Strep, 75 U/mL collagenase B (Sigma),
20 μg/mL Dispase I (Roche, Welwyn Garden City, UK)).
The cells were then washed gently in PBS. For flow
cytometric analysis tissue cells were fixed with 1% para-
formaldehyde and stored at 4 °C. For RNA expression
analysis preparations were resuspended in 1 mL of RLT
Plus buffer (Qiagen, Manchester, UK) containing 1 μL/mL
β-mercaptoethanol prior to RNA extraction.
Isolation and stimulation of PBMC
PBMC were isolated by density gradient centrifugation
(Histopaque 1083 (Sigma), resuspended in tissue culture
medium ([TCM]; RPMI +10% foetal calf serum, 5 × 10−5 M
β-mercaptoethanol, 50 μg/mL gentamicin). Cell concentra-
tions were estimated using a haemocytometer, adjusted to
1 × 107 cells/mL then aliquoted (5 × 106 cells) for MAP
and HAV transgene PCR or stimulated with either
10 μg/mL PPD-J (a kind gift from D Bakker, CVL,
Lelystad, Netherlands) or an equal volume of TCM
alone as control for 24 h at 37 °C in 5% CO2 in air. Stim-
ulated or unstimulated PBMC were then pelleted and
supernatants stored at −70 °C prior to cytokine analysis
by ELISA. Parallel stimulations were established for the
subsequent analysis of cytokine expression by qPCR and
multiparametric analysis of cell populations by flow
cytometry.
DNA extraction
Pelleted samples were suspended in 600 μL GTC buffer
(4 M Guanidium thiocyanate (Sigma), 10 mM TrisHCl,
pH 8.0, 1 mM EDTA), transferred to a 1.5 mL lysing
matrix B ribolyser tube (MP Biomedicals, Leicester, UK)
mixed and lysed overnight at 4 °C. DNA extraction in-
cluded mechanical disruption in a FastPrep-24 ribolyser
(MP Biomedicals) at 6500 rpm for 45 s followed by
standard extraction using phenol/chloroform, chloroform/
isoamyl alcohol and precipitation overnight at −20 °C with
7.5 M ammonium acetate in ethanol [25].
MAP specific PCR
qPCR of DNA extracted from tissue samples was per-
formed as previously described with minor adjustments
[26]. Briefly, reactions comprised 2 μL DNA sample,
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Paisley, UK), 2 pMoles primer pair (AV1: ATGTGGTT
GCTGTGTTGGATGG, AV2: CCGCCGCAATCAACTC
CAG), made to 25 μL with RNAse free water. PCR cycling
used 95 °C: 15 min (1 cycle); at 95 °C: 30 s, 58 °C: 1 min,
72 °C: 1 min (40 cycles) with data collection at 76 °C (10 s)
using a CFX96 qPCR cycler (BioRad, Hemel Hempstead,
UK). Sample copy numbers were estimated from an aver-
aged value of three qPCR’s on each sample using a dilution
curve of a control total genomic DNA MAP K-10 stock
preparation serially diluted 10 fold to contain between 1 ×
102-108 genome equivalents. Nested MAP specific PCR of
DNA extracted from PBMC and liquid pre-culture faecal
sample preparations was performed as previously de-
scribed [25].
HAV transgene specific PCR
Blood and faecal samples taken 1 week prior to prime
vaccination then at intervals post vaccination (week -10,
-4, 0, 6 and 33) and spleen samples taken post mortem
(week 38) from each vaccinated animal were screened
for the presence of the HAV transgene. DNA was ex-
tracted from PBMC and tissue samples as described
above. Faecal samples (200 mg) were processed using a
QIAamp Stool DNA extraction kit (Qiagen) using a
standard protocol optimised for viral DNA extraction
[27]. DNA extracted from MVA.HAV cultured in CEF
cells (48 h: MOI 50:1) using either blood or faecal ex-
traction method were used as positive reagent/lysis con-
trols. PCR sensitivity was estimated at 20-50 copies
(positive in > 80% replicates) by dilution curves of a ref-
erence DNA standard stock comprising a plasmid con-
taining one copy of the HAV transgene construct.
RNA extraction and cDNA generation
Total RNA was isolated from PBMC stored in 1 mL of
RLT Plus buffer (Qiagen) containing 1 μL/mL β-
mercaptoethanol using the ALLPrep DNA/RNA mini kit
(Qiagen) and the robotic workstation for the automated
isolation of DNA and RNA, Qiacube (Qiagen), according
to manufacturer’s instructions. First strand cDNA was
synthesised from 250 ng mRNA sample aliquots using
standard reverse transcription reaction buffer (10 mM
dNTPs (Bioline, London, UK), 500 μg/mL oligo(dT)15
primers (Promega, Southampton, UK), 5 × RT Buffer,
0.1 M DTTand Superscript II Reverse Transcriptase (Invi-
trogen, Paisley, UK)) denatured at 65 °C for 10 min and
incubated at 42 °C for 50 min.
cDNA qPCR for IL-17, IL-22 and IL-23 expression
IL-17, IL-22, IL-23 and the reference gene GAPDH were
amplified by qPCR using the LightCycler 480 DNA
SYBR Green I Master on the LightCycler 480 qPCR ma-
chine (Roche). The primers and conditions used were:IL-17A: FW: TAACCGGAGCACAAACTCCAGA ; RV:
GGTGGAGAGTCCAAGGTGAGGT; 95 °C: 5 min
(1 cycle), then 95 °C: 20 s, 62 °C: 20 s, 72 °C: 30 s (45 cy-
cles): IL-22: FW: CCGCTGGCTGCCTCCTT; RV: AGGG
CTCCTGGAAGTCGGA ; 95 °C: 5 min (1 cycle), then 95 °C:
20 s, 60 °C: 20 s, 72 °C: 30 s (40 cycles): IL-23: FW: ACC
AATGGGACATGTGGATCTAC; RV: AGGGCTTGGAG
TCTGCTCAGTT: 95 °C: 5 min (1 cycle), then 95 °C: 20 s,
60 °C: 20 s, 72 °C: 30 s (45 cycles): GAPDH: FW: GATG
CTGGTGCTGAGTATGTAGTG RV: ATCCACAACAG
ACACGTTGGGAG 95 °C: 5 min (1 cycle), then 95 °C:
20 s, 60 °C: 20 s, 72 °C: 45 s (40 cycles).
All reactions were run in duplicate in a final volume of
20 μL. Relative gene quantities were calculated using
LightCycler480 1.5.0 software by comparing each sample
with a serial dilution of standard PCR purified products
in the same run. Concentrations of genes of interest
were then calculated from standard curves in arbitrary
units. Antigen-specific gene induction was calculated ac-
cording to the method described by Pfaffl [28] from
values of each target gene normalized to the reference
gene (ref; GAPDH) for each sample. Briefly, values were
calculated according to the following:
Ratio ¼ Etarget
 ΔCp target control‐sampleð Þ
Erefð ÞΔCp ref control‐sampleð Þ
Where E is efficiency calculated by the standard curve
for each gene and ΔCp is the difference calculated by
the Lightcycler of the samples treated with media alone
minus the samples treated with PPD-J.
MAP culture
Samples were decontaminated and extracted following
previously described recommended guidelines [29] then
cultured on liquid Middlebrooks 7H9 medium [24] at 37 °C
for 2 weeks, then plated onto the same medium (with added
agar) and incubated for up to 12 weeks or until colonies
appeared. PBMC samples (2 × 106 cells) were added to
5 mL of sterile distilled water and lysed for 30 min then
centrifuged for 15 min at 3500 × g and the pellet resuspended
in 1 mL modified liquid Middlebrooks 7H9 medium and
cultured as faecal samples. Colony identity was confirmed
with MAP specific PCR as above and representative isolates
from the initial inoculum and a final faecal sample also sub-
jected to MIRU typing.
MAP killing assay
Whole blood (15 mL) in EDTA tubes was mixed with
15 mL PBS and centrifuged at room temperature onto
15 mL Histopaque 1083 (Sigma) for 1200 × g for 1 h
with no brake applied. Buffy coats were pipetted off and
washed once in PBS. Cells were diluted to 1 × 107/mL
in RPMI medium (RPMI1640, 10% FCS, 50 μg/mL
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tissue culture plates at 4 × 105 cells per well in quadru-
plicate. Two duplicates were activated with 30 ng/mL
bovine IFN-γ (Fisher Scientific, Loughborough, UK) then
incubated at 37 °C in 5% CO2 overnight to attach. Media
was exchanged with 200 μL of RPMI containing 8 × 105
luminescent MAP 19698 L [30] and incubated for 5 days
in 5% CO2, changing media at 3 days. Cells were washed
once in PBS then lysed in 200 μL 0.4% SDS final in PBS
and read immediately in an injector Luminometer Glo-
Max 20/20 (Promega) set at 1 s delay, using 1% v/v
decanal (Sigma) as substrate. Relative killing values were
calculated as the percentage of luminosity lost from an
average of both IFN-γ activated and non-activated in-
fected cell cultures relative to an RPMI only infection
control set of wells.Whole blood IFN-γ release assay
Whole blood IFN-γ release assay was performed as previ-
ously described [31]. Briefly heparinised whole blood was
stimulated within one hour of sampling with either PBS
(control), avian-purified protein derivatives (PPD-A) at
4 μg/mL final concentration (Veterinary Laboratories
Agency, Guildford, UK), bovine-purified protein derivative
(PPD-B) at 8 μg/mL final concentration (Veterinary
Laboratories Agency, UK), and Johnin-purified protein de-
rivative (PPD-J) at 4 μg/mL final concentration (Central
Veterinary Institute, Copenhagen,Denmark), pokeweed
mitogen (Sigma) (positive control) and a set of peptides
(Pool J) spanning MAPK_1565 (C-term) plus MAP
K_2533 (N-term) region of the HAV transcript (GK
RHTQAVLALARRR; QAVLALARRRLNVLW; LARRRL
NVLWAMLRD; LNVLWAMLRDHAVYH; AMLRDHA
VYHPATTT; HAVYHPATTTAAARL; SIVGQTYRE
VEVVLD; TYREVEVVLVDGGST; EVVLVDGGSTDRT
LD; DGGSTDRTLDIANSF) at a final concentration of
2 μg/mL each [23]. After 24 h, plasma was tested in dupli-
cate by Bovigam ELISA (Prionics, Lelystad, Netherlands)
for the release of bovine IFN-γ. Values are expressed as a
Net OD (OD of antigen stimulated sample minus OD of
negative control).ELISA for IL-1β and IL-10 expression
The supernatants were assessed for the presence of
IL-1β using a bovine IL-1β kit (Thermofisher, Loughbor-
ough, UK) and for IL-10 as previously described [32].
The concentration of IL-1β is expressed as pg/mL and
for IL-10 as biological units (BU)/mL relative to a
standard curve. For IL-10 the standard preparation was
CHO cell expressed IL-10 (a kind gift from G Entrican,
Moredun Research Institute, Edinburgh). Each sample
assayed was measured in duplicate by ELISA; the vari-
ability between samples was less than 5%.Multi-colour immunofluorescent labelling
PBMC stimulated for 24 h with PPD-J or TCM were har-
vested and subjected to multi-parametric staining proto-
cols. Unless indicated all primary monoclonal antibodies
were from AbD-Serotec (Kidlington, UK) and secondary
antibodies were: goat anti-mouse IgG1-alexa-fluor 647 (Life
Technologies, Paisley, UK), goat anti-mouse IgG2a-PECy7
(Abcam, Cambridge, UK), goat anti-mouse IgG2b-RPE and
goat anti-mouse IgG3-FITC (Cambridge BioScience,
Cambridge, UK). All antibodies were used at predetermined
optimal concentrations. The fluorescence without the pres-
ence of primary mAb was used as a control for analysis.
Four colour flow cytometry was utilised to define cell sub-
sets. T lymphocyte subsets were detected using mAbs spe-
cific for bovine CD4 (CC30, IgG1 or CC8, IgG2a), CD8
(CC58, IgG1 or CC63, IgG2a), the WC1 γδ TCR (CC15,
IgG2a) or pan-γδ TCR (GB21a, IgG2b; VMRD, Pullman,
USA). The expression of CD25 (IL-A111, IgG1) and
CD45RO (IL-A116, IgG3) was determined on subsets of T
cells. Intracellular expression of FoxP3 was determined
within cells that were fixed with 1% paraformaldehyde and
permeabilised (BD FACSPerm) using mAb Fox5A (anti-bo-
vine Foxp3, IgG1 [33]; a gift from Professor WC Davis,
Washington State University, USA). For intracellular stain-
ing of IFN-γ, cells were pre-incubated with TCM with and
without PPD-J supplemented with PMA, ionomycin and
brefeldin A (Sigma), then fixed and permeabilised as
described above. Cytokine expression was determined
using anti-bovine IFN-γ (CC330, IgG1). Flow cytometric
analysis was conducted using the FACSCalibur (for
intracellular IFN-γ expression) or the LSR II Fortessa
(Becton Dickinson) and a minimum of 10 000 events
were collected. Flow cytometric data was analysed using
FlowJo software (v.7.6.5).
Statistical analysis
Group sizes were calculated using G*Power program
(v.3.15) based upon standard deviations from a similar
study [31] calculated at alpha significance of 0.05 to derive
an expected 90% power probability using a two tailed
t-test. Statistical analyses were calculated using a standard
statistics package software (GraphPad Prism v.6.04, La
Jolla, USA) or in SAS using a mixed model for repeated
measures analysis.
Results
Vaccination and general condition of animals
Calves were vaccinated at week -11 with Ad5-HAV,
boosted at week -5 with MVA-HAV (HAV vaccinated
group) then challenged orally with MAP at week 0. A
second group were vaccinated and challenged under the
same regime but with Ad5-GFP and MVA-GFP controls
(Sham vaccinated group). Vaccine preparations gave no
adverse reactions at any time during the experiment. No
A*
*
*
*
*
**
*
*
**
*
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the vaccination sites. PCR for HAV transgene specific
DNA, carried out on blood and faecal samples taken at
intervals throughout the experiment and spleen tissue at
necropsy, was uniformly negative demonstrating that no
vaccine was shed from the animals (data not shown). One
calf in the Sham vaccinated group developed an unrelated
illness (determined by post-mortem examination as septi-
caemia related to a navel infection) 3 weeks post vaccin-
ation and was euthanized. All other calves appeared healthy
throughout the experiment. There was no significant de-
crease in the final body weights of the groups (data not
shown). It became evident during data analysis that there
were distinct phases in several parameters that differed
between groups. We therefore report these findings in rela-
tion to each of these sequential phases.*
C
B
Figure 1 Whole blood PPD-J stimulated IFN-γ release assay. IFN-γ
release from A. PPD-J, B. PPD-A, C. PPD-B stimulated whole blood
taken from HAV vaccinated (black triangles) and Sham vaccinated (grey
squares) calves including samples taken week -11, immediately prior
prime vaccination; week -5, immediately prior boost vaccination; week
0, immediately prior to MAP challenge and up to 33 weeks post
challenge. OD values are adjusted to internal controls to remove assay
variation between runs. Significance indicated as *P <0.05, **P <0.01.Pre-challenge
All of the calves in the HAV vaccinated group, but not
the Sham vaccinated group responded to vaccination
with an increase in MAP (PPD-J) specific IFN-γ release
(Figure 1A). A significant increase (P < 0.05) in the level
of PPD-J specific IFN-γ released from stimulated whole
blood was evident at one week post-MVA-HAV boost-
ing and this remained significantly elevated throughout
all but one testing month in the experimental period
(P < 0.05). By contrast no PPD-J specific IFN-γ was
detected following Sham vaccination. Increases in avium
(PPD-A) and bovine (PPD-B) specific IFN-γ release
were also evident in the HAV- but not the Sham vacci-
nated calves immediately post-MVA boost but these did
not reach significance and rapidly declined to baseline
prior to challenge (Figure 1B and C). In parallel we
assessed IFN-γ release by whole blood stimulated with a
pool of HAV specific peptides in order to determine
whether these could be used to distinguish vaccinated
from infected animals (DIVA). In response to HAV pep-
tides we observed a significant increase in IFNγ re-
sponses (P < 0.05) from blood of HAV vaccinated but
not Sham vaccinated animals. This remained elevated
for the duration of the experiment (Figure 2).
In stimulated PBMC we observed differences in PPD-J
specific IFN-γ expression by subsets of T lymphocytes
from HAV (Figure 3A) and Sham (Figure 3B) vaccinated
calves. In Sham vaccinated calves no significant differ-
ences in the percentage of cells expressing IFN-γ in re-
sponse to PPD-J were observed pre-challenge. By
contrast, significant differences (P < 0.05) in PPD-J spe-
cific CD4+IFN-γ+ and CD8+IFN-γ+ cells were observed
pre-challenge in HAV vaccinated calves which peaked
2 weeks (week -9) post Ad5-HAV vaccination. No differ-
ences were observed in IFN-γ expression by WC1+ γδ
TCR+ T cell populations.
*** *
*
*
*
Figure 2 DIVA testing. IFN-γ release from HAV specific peptide
pool stimulated whole blood taken from HAV vaccinated (triangles)
and Sham vaccinated (squares) calves between week 0, immediately
prior to MAP challenge and 33 weeks post challenge. OD values are
adjusted to internal controls to remove assay variation between runs.
Significance indicated as * P < 0.05.
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Post oral MAP challenge (week 0) we systematically
assessed antigen-specific immune responses in whole
blood and isolated PBMC populations, the presence of
MAP DNA in blood and faecal samples and macrophage
killing efficacies. One week following oral challenge
PBMC isolated from 5/6 (83%) HAV vaccinated and
from 4/5 (80%) Sham vaccinated calves became MAP
PCR positive and 3/5 (60%) Sham vaccinated calves shed
MAP in faeces (Figure 4). Faecal cultures for HAV vacci-
nated calves were negative for MAP throughout the
experiment. Two weeks following challenge PBMC from
3/6 (50%) HAV vaccinated and 2/5 (40%) Sham vacci-
nated calves were positive for MAP by PCR and 1 of the
5 calves (20%) in the Sham vaccinated group was still
shedding MAP in the faeces (Figure 4). At week 1 post
challenge a transient but significant (relative to week 0)
peak in the percentage of PPD-J specific IFN-γ+ T cells
(CD4+, CD8+; P < 0.001) and WC1+ subsets (P < 0.01)
was observed in all animals (Figure 3). In whole blood
significantly (P < 0.05) higher levels of PPD-J specific
IFN-γ release were also detected in the HAV vaccinated
group compared to the Sham vaccinated calves and this
remained significantly elevated throughout the course of
the experiment (Figure 1). Alongside alterations in T cell
populations expressing IFN-γ occurring at this early
time point post-MAP challenge, we observed a signifi-
cant increase in IL-22 (P < 0.05) and a trend towards
increased IL-17 expression in the HAV vaccinated but
not the Sham vaccinated animals (Figure 5).Immediately prior to challenge PBMC isolated from
Sham vaccinated calves were equally capable of killing
MAP compared to PBMC from HAV vaccinated calves.
However, within one week of challenge the efficacy of
PBMC fractions to kill MAP dropped dramatically by
~30% in the Sham group whereas the capacity for MAP
killing was retained within the HAV animals (Figure 6).
This large drop in killing efficacy was of relatively short
duration with some recovery of killing capacity by
2 weeks post-challenge but a significant difference (P <
0.05) between HAV and Sham vaccinated animals
remained evident between weeks 1 to 24 post-challenge.
Post challenge (6-19 weeks)
Significant differences between the HAV and Sham
vaccinated groups across a range of parameters were
observed between weeks 6 and 14. The MAP killing
capacity of PBMC from the Sham vaccinated group
remained reduced (Figure 6) and there was an increase
in the number of animals with MAP positive PBMC.
PBMC from one animal were positive for MAP by PCR
in each group at week 11 and this had increased to 4/5
(80%) Sham vaccinated and 2/6 (33%) HAV vaccinated
calves positive at 14 weeks (Figure 4).
Within a similar timeframe altered cytokine expression
profiles were detected with significant differences be-
tween the HAV and Sham vaccinated groups (Figure 7).
Levels of IL-1β peaked at week 11 (Figure 7A) followed
a few weeks later by IL-10 (Figure 7B) with a signifi-
cantly greater increase (P < 0.05) in the secretion of both
cytokines by PPD-J stimulated PBMC isolated from
Sham vaccinated calves when compared to the HAV vac-
cinated group. In contrast an increase in PPD-J specific
IFN-γ secretion was evident in the HAV vaccinated
group at week 11 (Figure 1A) and antigen-specific ex-
pression of IFN-γ was significantly elevated in CD4+,
CD8+ and WC1+ T cells from HAV vaccinated animals
between 11 and 19 weeks (Figure 3A). No significant
increases in IFN-γ were detected in Sham vaccinated
animals in this time period. Within PBMC, alterations in
the number of PPD-J stimulated cells expressing FoxP3
were evident from week 14 post-challenge with signifi-
cant increases in CD4+FoxP3+ cells evident in the Sham
vaccinated group at weeks 14 and 19 (P < 0.05;
Figure 8A).
Post challenge (20 - 38 weeks) and post-mortem
Towards the end of the challenge period the differences
between HAV vaccinated and Sham vaccinated animals
became more pronounced for a number of the measured
parameters. The MAP killing capacity of the PBMC frac-
tion returned in the Sham vaccinated group to levels
similar to that of the HAV vaccinated group (Figure 6).
The frequency of detection of MAP within PBMC
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Figure 3 Intracytoplasmic expression of IFN-γ by sub-populations of peripheral T cells in HAV and Sham-vaccinated calves. Percentage
of live CD4+ (squares), CD8 + (triangles) WC1 + (crosses) expressing IFN-γ after 24 h stimulation with PPD-J from A. HAV vaccinated calves B. Sham
vaccinated calves including samples taken week -11, immediately prior prime vaccination; week -5, immediately prior boost vaccination; week 0,
immediately prior to MAP challenge and up to 36 weeks post challenge. Significant differences between groups in A. and B. of P < 0.05 are
indicated as † (CD4+), * (CD8 +), φ (WC1 +) for each time point.
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http://www.veterinaryresearch.org/content/45/1/112increased in the Sham vaccinated group with 3/5 ani-
mals being consistently positive and all animals in this
group testing positive at least once during this period
(Figure 4). In contrast PBMC from 4/6 HAV vaccinated
calves remained consistently negative and 2/6 only
tested positive once within this period (Figure 4).Antigen-specific cytokine levels decreased from week
20 onwards. At week 24 in the HAV vaccinated group
significantly elevated levels of PPD-J specific IL-22 and
raised levels of IL-17 were observed compared to the
Sham vaccinated calves (Figure 5) which decreased along
with antigen specific IL-1β and IL-10 over time
Figure 4 MAP PCR positivity in blood and faeces of HAV and
Sham vaccinated calves. Percentage of animal samples that were
positive for MAP by PCR. MAP was assessed in PBMC from HAV
vaccinated calves (triangles), PBMC from Sham vaccinated calves
(squares) and faeces from Sham vaccinated calves (crosses). Faeces
of HAV vaccinated calves were consistently negative (data not
shown) from immediately prior to boost vaccination (week -5) up to
36 weeks post challenge.
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http://www.veterinaryresearch.org/content/45/1/112(Figure 7). IL-10 levels remained significantly higher in
the Sham vaccinated compared to the HAV vaccinated
calves throughout the remainder of the study period.
The percentage of PPD-J specific IFN-γ expressing
cells (Figure 3) and secreted IFN-γ (Figure 1) began to
decrease in the HAV vaccinated group during this final
stage whilst levels in the Sham vaccinated group
remained low. A highly significant increase (P < 0.001)
in PPD-J specific FoxP3 expressing CD4+ (Figure 8A),
WC1+ (Figure 8B) and CD8+ (Figure 8C) T cells was
observed in the Sham vaccinated group compared to
the HAV vaccinated animals from week 24 onwards
(Figure 8).
Standard tuberculin skin testing was carried out at
week 36. All calves had similar skin reactivity to both
PPD-A and PPD-B. The difference in PPD-B:PPD-A spe-
cific response was consistently < 1 mm indicating that
none of the calves would be classified as TB reactors
(see Additional file 1). At this time point DIVA testing
using HAV specific antigens could still identify the HAV
vaccinated from the Sham vaccinated calves (Figure 2).
Examination of tissues taken post-mortem (38 weeks)
revealed significant differences between the HAV vacci-
nated and Sham vaccinated groups. Measurement of the
number of MAP present within tissues demonstrated
significant reductions in load averages between HAV and
Sham groups with samples obtained from duodenum
(P = 0.003), jejunum (P = 0.009) and spleen (P = 0.002)
(Figure 9). A significant decrease (P = 0.016) in overall
total load was also observed when averages of all 5 sites
were combined. All calves had at least one tissue sample
positive for MAP indicating that whilst there was asignificant degree of protection based on a significant
reduction in bacterial load, sterilising immunity was not
induced by HAV vaccination. All tissue samples from
Sham vaccinated calves were positive for MAP. By con-
trast only 36/106 (34%) of all samples and 8/36 (17%)
jejunum samples from the HAV vaccinated group were
positive for MAP by qPCR. Nearly half (48%) of the total
load present in HAV animals was located in mesenteric
lymph node samples with 38% represented in one lymph
node sample alone.
MAP cultured from two samples was shown to have
the same genomic identity profile as the challenge strain
(see Additional file 2). There were no obvious clinical
manifestations or major macroscopic lesions at post
mortem suggestive of progression towards clinical JD in
any of the calves. Assessment of lymphoid cell popula-
tions within gut mucosal tissue from the ileum, ileocae-
cal valve region and associated lymph nodes showed
larger populations of CD4+FoxP3+, CD8+FoxP3+ and
WC1+FoxP3+ cells in the Sham vaccinated group com-
pared to the HAV vaccinated group with the latter two
reaching statistical significance (P < 0.05; Figure 10).
There was also trend towards an increased presence of
IL-17 and IL-22 in lymph node tissue of the HAV vacci-
nated group but this did not reach significance (see
Additional file 3).
Discussion
Johne’s disease (JD) is a disease with economic signifi-
cance in many dairy producing countries. Despite aware-
ness of the problem and long term implementation of
extensive control policies, MAP prevalence in domestic
livestock worldwide has been rapidly increasing, particu-
larly in dairy cattle. Vaccination is the most cost effective
disease control measure but current whole cell killed JD
vaccines have limited efficacy and are incompatible with
diagnosis of MAP infection. Notably these also interfere
with bovine tuberculosis tuberculin skin tests. In previ-
ous studies using a mouse model we have shown that a
prime-boost viral delivery regimen of early entry MAP
specific antigens (HAV vaccine) showed significant pro-
tection and efficacy in prevention of colonisation [23].
In this study we have applied this approach to cattle
and shown that prime-boost HAV vaccination prior to
MAP challenge offered a high degree of protection rela-
tive to a Sham vaccinated challenged group. We report
protective capacity as an ability of vaccination to signifi-
cantly reduce bacterial numbers in peripheral blood, gut
tissues and in faeces as this is likely to impact signifi-
cantly on disease progression and transmission.
Significant infection of Sham vaccinated calves with
MAP was shown herein. MAP could be detected in
100% of tissue samples at 38 weeks post challenge at
high numbers (up to 5 logs of MAP load per gram of
*A
B
C
Figure 5 Expression of antigen specific IL-17, IL-22 and IL-23 by PBMC from HAV- and Sham-vaccinated calves. Fold increases, relative to
GAPDH. in expression of cytokines A. IL-17, B. IL-22 and C. IL-23 measured by qPCR from RNA extracted from 24 h PPD-J stimulated PBMC isolated
from HAV vaccinated (triangles) or Sham vaccinated (squares) calves, taken immediately prior to MAP challenge (week 0) up to 36 weeks post
challenge. Significance between groups is indicated as * P < 0.05.
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Figure 6 MAP killing efficiency of macrophage fractions.
Percentage of an initial MAP inoculum killed after infection for 5 days
in macrophages isolated from HAV vaccinated (diamonds) or Sham
vaccinated (squares) calves taken immediately prior to HAV boost
(week -5) up to 36 weeks post challenge. Values given are averages of
bovine IFN-γ stimulated and unstimulated preparations performed in
duplicate. Significance between groups is indicated as * P < 0.05,
** P < 0.01, *** P < 0.001.
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http://www.veterinaryresearch.org/content/45/1/112tissue) and shedding was detected at least once in faecal
samples from 3/5 Sham vaccinated challenged animals.
Contrastingly, all faecal samples and at least one tissue
sampling site from 4/6 HAV vaccinated calves tested
negative (less than 100 organisms per gram) for the
presence of MAP.
This reduction in faecal shedding would have a major
impact on disease control strategies and would contrib-
ute to minimising animal to animal spread of MAP in-
fection. Examination of a range of immunological
parameters suggested that these occurred in distinct
phases related to the infectious load of MAP and these
differed between HAV and Sham vaccinated animals.
During the initial phase HAV vaccination significantly
primed and boosted antigen specific CD4+, CD8+ but
not WC1+ IFN-γ producing T-cell populations. No ad-
verse events and no excretion of vaccine were detected
one week and up to 43 weeks post vaccination indicating
that, as in other studies, MVA and adenoviral delivery
systems are well tolerated in cattle. The DIVA peptide
pool used, despite being derived from MAP specific epi-
topes, showed reactivity only with HAV vaccinated
animals and was significantly raised throughout the ex-
periment. Reactivity was not increased after MAP chal-
lenge and importantly no response to the HAV specific
peptides was observed in in Sham vaccinated animals
post-MAP challenge suggesting that these epitopes are
not recognised during early natural MAP infection in
cattle. In addition none of the cattle in the current study
tested positive in the tuberculin skin test used fordiagnosis of bovine TB. This is important as it is essen-
tial not only to be able to distinguish HAV vaccinated
from MAP infected cattle in DIVA tests but also to be
able to identify these from cattle infected with M. bovis.
This will be of particular importance in countries with
ongoing bovine TB control programmes such as the UK.
All animals were challenged orally with MAP, which
resulted in rapid and efficient uptake as demonstrated
by the high degree of transient MAP bacteraemia in the
peripheral blood observed at week 1 post-challenge.
Some early passive shedding was seen along with pro-
inflammatory Th1 immunological responses and T cell
proliferative responses characteristic of established MAP
infection [34]. Importantly in the HAV vaccinated group
we observed a more rapid and significantly higher ex-
pression of IFN-γ compared with the Sham-vaccinated
cattle likely to indicate early Th1 polarisation. This en-
hanced secretion of IFN-γ in HAV vaccinated calves
could activate macrophages for enhanced cytotoxicity.
Indeed in this study we demonstrated that macrophages
from HAV vaccinated cattle had, at early time points
post-infection, significantly greater capacity to kill MAP
compared to PBMC taken from Sham vaccinated ani-
mals. This may be a crucial early event determining the
eventual outcome of infection. Interestingly, early post-
challenge there was a dramatic loss in the capacity of
PBMC derived macrophages to kill MAP that was only
observed in the Sham vaccinated animals and not the
HAV vaccinated calves. This may reflect the capacity of
MAP to actively evade killing within macrophages and
to alter their lytic capacity such that in infected calves
the normal killing capacity is significantly reduced. An
alternative, but not exclusive explanation is that HAV
vaccination induced immune responses (including IFNγ
release and T cell activation) activate macrophages for
enhanced killing. Our studies have not defined which
parameters are required for the maintenance of killing
capacity observed in HAV vaccinated cattle but this will
be an important aspect to dissect in future studies.
After 2 weeks the number of animals with MAP detect-
able within PBMC declined; this was evident in both the
HAV vaccinated and Sham vaccinated animals. For the
remainder of the experiment only one animal in the HAV
vaccinated group continued to have persistent MAP
present in the PBMC fraction. However, in the Sham vac-
cinated animals the reduction observed at 2 weeks was
transient and persistent bacteraemia returned, consistent
with the hypothesis that vaccination significantly affects
the capacity of the host to control MAP. The transient
reduction in the number of MAP present within the blood
of Sham vaccinated animals may correspond to a trans-
location of MAP to tissues where they begin to divide be-
fore again populating the blood at later stages of infection.
By contrast the ongoing immune response in the HAV
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Figure 7 Secretion of IL-1β and IL-10 by PBMC from HAV- and Sham-vaccinated animals. At the indicated time points post-MAP challenge
PBMC were isolated from HAV-vaccinated (triangle) or Sham-vaccinated (grey square) calves and stimulated for 24 h with PPD-J or left unstimulated
(control). Supernatants were assessed for the presence of A. IL-1β and B. IL-10 in triplicate by ELISA and concentrations of secreted cytokine were
assessed relative to standard curve. The mean +/- SD PPD-J specific (PPD-J induced cytokine concentration – unstimulated cytokine concentration) is
shown for n = 6 (HAV-vaccinated) or n = 5 (Sham-vaccinated) animals including samples taken week -11, immediately prior prime vaccination; week
-5, immediately prior boost vaccination; week 0, immediately prior to MAP challenge and up to 36 weeks post challenge. Significance between groups
is indicated as * P < 0.05, ** P < 0.01.
Bull et al. Veterinary Research 2014, 45:112 Page 12 of 17
http://www.veterinaryresearch.org/content/45/1/112vaccinated calves is likely to contribute to the level of
MAP proliferation and/or survival. Rapid dissemination
of MAP post infection and consistent bacteraemia has
been demonstrated in several animal models for at least
72 hours post challenge [35]. Long term bacteraemia in
naturally infected animals has been linked with progres-
sion towards disease, particularly that of the multibacillary
type [36]. Thus, early control of peripheral bacteraemia by
vaccination may be critical for long term protection from
disease.Small increases in IL-17 were also detected in HAV
vaccinated cattle early post-infection, however due to a
lack of antibodies for detection of intra-cytoplasmic IL-
17 in cattle, we were not able to determine the cellular
source of IL-17 herein. Both IFN-γ and IL-17 have been
implicated as protective cytokines induced by MAP vac-
cination in previous studies [37]. Conversely, the cyto-
kine response in the Sham vaccinated animals at early
time points were dominated by IL-1β and IL-10 with lit-
tle induction of IFN-γ. Similar profiles have previously
***
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Figure 8 FoxP3 expression by T cell sub-populations from HAV-
and Sham-vaccinated animals. PBMC from HAV-vaccinated (diamond)
or Sham-vaccinated (square) calves were stimulated for 24 h with PPD-J
or left unstimulated (control), then washed, fixed, permeablised and
assessed for expression of A. CD4, B. WC1 and C. CD8. Cells were gated as
live PBMC and the percentage of each cell population (CD4, CD8, WC1)
expressing FoxP3 was calculated. Samples taken include week 0,
immediately prior to MAP challenge and then up to 36 weeks post
challenge. Significance between groups is indicated as * P < 0.05,
** P < 0.01, *** P < 0.001.
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http://www.veterinaryresearch.org/content/45/1/112been associated with late stage intracellular processing
of mycobacteria [38] and progression of MAP infection
[39]. The source, timing and magnitude of IL-10 produc-
tion can be a major determinant on disease outcome
[40] and the induction of an IL-10 response in animals
with significant MAP burden (i.e. the Sham vaccinated
calves) is an indicator of immune regulatory imbalance
which could facilitate intracellular mycobacterial survival
[41]. A number of studies have shown the source of IL-
10 from MAP infected cattle to be largely CD4+ T cells,
although monocytes may also be involved. In vitro up-
regulation of expression of IL-10 is a major response
mechanism of bovine macrophages infected with MAP
and is associated with reduced IFN-γ secretion and
immune evasion. In bovine intestinal tissues early post-
infection, MAP induces anti-inflammatory genes such
as IL-10 [42] associated with increased intracellular
survival. Furthermore we have recently demonstrated
that knockdown of IL-10 by siRNA significantly inhibits
intracellular survival of BCG indicating a key role for
IL-10 in enabling mycobacterial growth and persistence
in macrophages (Professor Liz Glass, personal communi-
cation to J Hope).
Up-regulated IL-1β has been described in the tissues
of animals affected by JD [40], the expression of which
appeared to correlate with inflammation. In an epithelial
cell line-bone marrow-derived macrophage (bMDM) co-
culture model, MAP invasion of the epithelial cells
induced up-regulation of IL-1β, leading to the transmi-
gration of the bMDM [43]. This may be a mechanism
whereby MAP promotes its own uptake and intracellular
survival. Since IL-1β (along with IL-23/IL-17) is regu-
lated by autophagy, interference with expression of these
cytokines could also indicate that MAP is directly sub-
verting this pathway to promote its survival within
macrophages enabling growth and establishment within
the host. This is in line with the decreased capacity of
PBMC to kill MAP that we observed in the infected
Sham vaccinated calves.
In the final phase of this study (> 19 weeks) MAP bac-
teraemia steadily increased and persisted in the Sham
vaccinated calves but stayed low in the HAV vaccinated
group. The final MAP load in tissues of HAV vaccinated
animals at 38 weeks was significantly reduced in gut and
lymphoid tissues with most (73%) gut mucosal tissue
samples testing MAP negative and the majority (55%) of
detectable MAP organisms were located in lymph nodes.
Faecal shedding was not an expected outcome measure
in this model due to the low challenge dose and short
study duration post challenge [30]. However abrogation
of faecal shedding is a major requirement for an effective
MAP vaccine [9] so it was interesting to note that all
HAV vaccinated animals were negative for MAP in fae-
cal samples collected throughout the experiment whilst
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Figure 9 MAP load in tissue 38 weeks post challenge. Mean and SEM of genome equivalents determined by MAP specific IS900 qPCR
(assuming 17 copies per organism) in weighed samples of various tissue sites (4 lymph node, 3 ileum, 6 jejunum, 2 duodenum, 1 spleen, per
animal) from HAV vaccinated (triangles) and Sham vaccinated (squares) calves taken 38 weeks post MAP challenge. Each point represents an
average of all samples taken from each tissue site in a single animal with individual sample values being derived from averages of duplicate qPCR
performed on DNA extracted from each sample. Mann-Whitney U tests show Sham vaccinated animals had significantly greater loads than HAV
vaccinated animals in duodenum (P = 0.003), jejunum (P = 0.009) and spleen (P = 0.002).
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http://www.veterinaryresearch.org/content/45/1/112intermittent faecal positives were detected in the Sham
vaccinated group.
Additionally in this final phase, the Sham vaccinated
group developed increased proportions of PPD-J reactive
FoxP3+ T cell populations which were also evident in gut
tissues taken at the end of the study period. This may be
consistent with the development of a regulatory population
of T cells, although we have not demonstrated herein that
these cells display such functions. Reduced CD4+ effector
T cell capacity and the development of regulatory T cellpopulations has been reported to correlate with disease
progression in other studies of MAP infection in cattle,
consistent with our observations [44,45]. Interestingly we
found significant alterations in the proportion of WC1+ γδ
TCR+ T cells present within the tissues of HAV vaccinated
compared to Sham vaccinated cattle. A significant propor-
tion of WC1+ γδ TCR+ T cells are regulatory, expressing
high levels of IL-10 [46,47] which could contribute to the
continued ability of MAP to proliferate within the tissue. A
caveat to the observations and interpretations of our data
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Figure 10 FoxP3 and CD45RO cell populations in gut tissue
38 weeks post challenge. Percentage of CD4+, WC1 +, CD8 + cells
in mucosal and lymph node tissue from ileal, ileocaecal valve sites A.
total fraction; B. fraction expressing FoxP3; C. fraction expressing
CD45RO from HAV vaccinated (black) or Sham vaccinated (grey)
taken 38 weeks post challenge. Significance between groups is
indicated as * P < 0.05, ** P < 0.01.
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http://www.veterinaryresearch.org/content/45/1/112is the relatively short duration of the experimental infec-
tion model used herein. More extensive studies in a long
term model or in a field study where natural exposure to
MAP occurs will be required to confirm whether we can
reproducibly eliminate faecal shedding. This would repre-
sent a major advance in disease control as breaking the
transmission cycle would have a significant impact on the
incidence and spread of disease within and between herds.
Such longitudinal studies in large cohorts of MAP exposed
cattle would enable us to define the impact of HAVvaccination not only on transmission but also on disease
progression. This is an essential next step in confirming
the protective efficacy of the HAV vaccine.
The majority of recent MAP vaccination strategies
have relied on MAP whole cell formulations to effect
nonspecific multi-antigen delivery, thus it is difficult to
make detailed comparisons between our novel specific
multi-epitope viral delivery and other vaccine regimens.
However, studies have shown that protective immunity
is associated with high IFN-γ levels and increased Th-17
related responses [22]. There is evidence that the failure
of whole cell vaccines to eliminate MAP shedding in fae-
ces may be due partly to interference from non-specific
immune regulators present in the mycobacterial cell wall
that can deflect appropriate induction of Th1 responses
critical for disease resolution [34] and reduce antigen
presentation [48]. By contrast HAV vaccination appeared
to induce appropriate immune bias, enhanced MAP-
specific killing and eliminated MAP shedding.
A long term challenge will be the implementation of
HAV vaccination in the field since the strategy that we
have assessed involves prime-boost with viral, genetically
modified, vectors rather than a single subunit vaccin-
ation. Assessment of the MAP-specific antigens con-
tained within the HAV vaccine in combination with
adjuvants or other delivery systems will be important, as
will determination of the duration of immunity induced
by vaccination and the long term impact of vaccination
on MAP infection and Johne’s disease in the face of po-
tential high-level exposure in heavily affected herds.
In conclusion we have shown that prime-boost viral
delivery of MAP antigens to young calves was well toler-
ated, vaccine was not excreted and vaccination was able
to prime a range of cell mediated immune responses
which may correlate with the induction of protective im-
munity. We have shown significant efficacy of HAV vac-
cination of young calves to reduce the tissue burden of
MAP associated with abrogated faecal shedding of MAP.
These features, alongside a clear capacity to differentiate
vaccinated from infected animals by a novel DIVA test,
lack of tuberculin cross reactivity and definition of im-
munological parameters associated with varied stages
post-infection highlight the promise of the HAV vaccine
for the improved control of MAP infection in cattle.Additional files
Additional file 1: Tuberculin testing of Sham vaccinated (grey) and
HAV vaccinated (black) animals 35 weeks post MAP challenge. Table
showing skin thickness measurements at separate PPA-A, PPD-B inoculum
sites pre and 72 h post inoculation. A standard positive tuberculin test
requires > 5 mm difference between PPD-B and PPD-A at 72 h. A standard
positive tuberculin test requires > 5 mm difference. No significant difference
between groups was demonstrated (P = 0.523) [49].
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http://www.veterinaryresearch.org/content/45/1/112Additional file 2: MIRU-VNTR typing of MAP isolates. Gel files
showing specific MIRU-VNTR PCR products profiles comparing Control
K10 reference strain, challenge strain MAP R0808 and a MAP isolate from
faeces of Sham vaccinated animal obtained at 36 weeks.
Additional file 3: IL-17 and IL-22 in tissue from Sham vaccinated
and HAV vaccinated animals 36 weeks post MAP challenge. Bar
graphs showing fold increases relative to GAPDH in expression of
cytokines Graph A. IL-17 and Graph B. IL-22 in mucosal and lymph node
tissue from ileal, ileocaecal valve sites obtained from HAV vaccinated
(black) or Sham vaccinated (grey) calves obtained 38 weeks post
challenge. There were no significance between groups (P > 0.05).
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